ABT vs REPL · P/E 25, rev $44.33B vs $825.7M cap
Abbott Laboratories (ABT) versus Replimune Group Inc (REPL) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Replimune Group Inc (REPL) is a biotechnology company listed on NASDAQ.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
REPL does not have a complete income-statement cache yet.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. REPL currently screens at market cap $825.7M.
Not investment advice. Open the ABT and REPL stock pages for the full models.
Not investment advice.